丁香实验_LOGO
登录
提问
我要登录
|免费注册
点赞
收藏
wx-share
分享

Identification of Peptides for Tissue-Specific Delivery

互联网

517
Antisense-mediated exon skipping has shown to be a promising therapeutic approach and is in clinical trials for Duchenne muscular dystrophy. However, after systemic treatment the majority of the injected antisense oligonucleotides (AONs) will not end up in the intended tissue. This mistargeting of AONs might have detrimental effects, especially with long-term treatment and continuous accumulation of AONs. Further, even when no detrimental effects occur, mistargeted AONs are lost for exon skipping in the intended tissue. One way to reduce the amount of mistargeted AONs is by adding a peptide that specifically binds to and is taken up by the intended tissue. Such peptides can be found by screening phage display libraries. With in silico , in vitro, and in vivo testing, the peptides that bind the intended tissue most efficiently and most specifically can be identified.
提问
扫一扫
丁香实验小程序二维码
实验小助手
丁香实验公众号二维码
扫码领资料
反馈
TOP
打开小程序